Searched for
RESPIRATORY THERAPIES
Child develops acute lung injury and multi-organ dysfunction after consuming mosquito-repellent liquidA 19-month-old child faced a life-threatening ordeal after accidentally ingesting mosquito-repellent liquid, leading to severe lung damage ...
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
Indian pharma market's double-digit growth momentum is likely to continue further: EquirusThe Indian Pharmaceutical Market is set for continued double-digit growth. May's performance showed strong demand across all therapies. Chr...
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
Oxymed unveils SleepEasy 2 AutoCPAP, strengthen products in healthcareEstablished in 2015 and headquartered in Bengaluru, the company says the new generation of AutoCPAP will help deliver better healthcare.
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
Wealth creation is also about ignoring noise on the street: 15 mid- and small-cap stocks from different sectors which fit the billIn the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...
Venus Remedies expands Latin America presence with Argentina nod for antibioticVenus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin Amer...
From care to commerce: How phydigital healthcare is turning patient programmes into big businessIndia's healthcare is changing. Value is moving from hospitals to patients' daily lives. A new 'phydigital' model combines physical and dig...
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
Mankind Pharma’s Rx for success: Aatmanirbhar push, affordable careMankind Pharma, guided by Ramesh and Rajeev Juneja, is a leading Indian pharmaceutical firm. The company focuses on mass-market drugs and h...
As monsoon takes hold, anti-infective, respiratory drugs' demand surgesMonsoon led to a surge in demand for respiratory, anti-infective, and anti-malarial products. The respiratory market saw a notable increase...
Domestic pharma market growth slips to 6% in JulySheetal Sapale, VP, commercial, Pharmarack, said four key therapy segments - cardiac, anti-infectives, gastro and respiratory - have driven...